Sign-on letter to Pfizer urging an immediate response to the nationwide shortage of pencillin G benzathine, the standard treatment for primary and secondary syphyilis.
July 21, 2017
Ian C. Read
c/o Margaret M. Madden
Senior Vice President and Corporate Secretary
Chief Governance Counsel at Pfizer Inc.
235 East 42nd Street,
New York, New York 10017
Dear Mr. Read,
We the undersigned urge Pfizer to adequately and promptly address the penicillin G benzathine (Bicillin-LA) shortage to ensure normal quantities in the United States. Bicillin-LA remains the preferred treatment for primary and secondary syphilis in adults, infants, and children, and the only approved treatment for syphilis in pregnant women. As the only manufacturer of pencillin G benzathine in the United States, Pfizer’s inability to provide adequate quantities of Bicillin-LA has left the Food and Drug Administration, the Centers for Disease Control and Prevention, and many city and state health departments scrambling to ration existing stockpiles of the drug and develop contingency plans.
Pfizer first reported a manufacturing delay in April 2016, but projected the shortage would be limited to the summer of 2016. More than a year later, the problem persists, with Pfizer reporting that the shortage will likely continue through the end of 2017. Given the unreliability of Pfizer’s timeline and its vague explanations of the manufacturing complications, key stakeholders are worried the situation will deteriorate further and extend into 2018.
Shortages of Bicillin-LA have been a recurring concern in the US in recent years. In 2002 Wyeth-Ayerst, the previous manufacturer of Bicillin-LA, created shortages in North America when it halted production of the product at a Canadian plant. In 2005, shortages reoccurred and persisted for nearly five years.[i] As we head into our second year of the most recent shortage, it is imperative that Pfizer not only invest all available resources to address the manufacturing problems, but be forthcoming with all stakeholders impacted by the shortage regarding the reason(s) for the delay and the company’s plans to safeguard against shortages in the furture.
The timely diagnosis and treatment of syphilis is a major public health priority in the United States. Between 2014 and 2015, the national primary and secondary syphilis rate increased 19% to 7.5 cases per 100,000 population, the highest incidence reported since 1994.[ii]
While much of the increase has been disproportionately experienced among gay and bisexual men, incidence also increased 27.3% among women in the same time period. Consequently, there has also been an increase in rates of congenital syphilis, which may result in stillbirth or infant death in up to 40% of cases. In 2015, there were a total of 487 reported cases of congenital syphilis, for a national rate of 12.4 cases per 100,000 live births. This rate represents a 6.0% increase relative to 2014 (11.7 cases per 100,000 live births) and a 36.3% increase relative to 2011 (9.1 cases per 100,000 live births).
Because Bicillin-LA is the only approved syphilis treatment for pregnant women, they remain an extremely vulnerable population when shortages occur. While alternative regimens for primary and secondary syphilis infections are theoretically possible in other populations, treatment becomes more complicated—with patients having to adhere to multiple daily doses over two weeks—and inferior to the penicillin G benzathine start of care, particularly from a public health perspective. The syphilis epidemic has already proven challenging to control, most notably in gay and bisexual men. If affected communities and public health officials in the United States must rely on a single manufacturer for the standard of care, that manufacturer must be held accountable for dereliction of duty to maintain adequate quantities. Unexplained manufacturing delays not only endanger the successful treatment of syphilis, it endangers efforts to cure people in a timely manner, stop onward transmission, and bring down rising new infection rates.
Affected communities and key stakeholders need to know the exact causes of the current shortage, including how Pfizer executives plan to use their enormous wealth and power to fix this situation and prevent it from happening again. Pfizer is reported to have total assets of $168 billion and is noted by Forbes as one of the American companies with the largest stockpiles of cash.[iii] We would hope that with such impressive resources, some shortage prevention efforts are well-funded and already making significant progress.
With its headquarters located in the heart of Manhattan on 42nd street, not far from Treatment Action Group and several other signatories of this letter, we would welcome an immediate in-person meeting with Pfizer to discuss solutions. TAG can be reached by emailing Jeremiah Johnson. At a minimum we expect prompt, transparent communication about the shortage to be immediately shared with affected communities to ensure all stakeholders are engaged in efforts to rectify this unacceptable situation and to prevent future recurrences.
Sincerely,
The following organizations:
ACRIA
New York
New York
ACT UP New York
New York,
New York
Action Wellness
Philadelphia
Pennsylvania
AIDS Alabama
Birmingham
Alabama
AIDS Foundation of Chicago
Chicago
Illinois
AIDS Project New Haven
New Haven
Connecticut
AIDS Project of the East Bay (APEB)
Oakland
California
Albany Damien Center
Albany
New York
Alliance for Living
New London
Connecticut
Alliance for Positive Health
Albany
New York
Amida Care
New York
New York
Bay Area Healthy Living Support Communication Platform-(BayHeal)
San Francisco
California
Berkeley Free Clinic
Berkeley
California
Callen-Lorde Community Health Center
New York
New York
Church Ladies for Choice
New York
New York
Coachella Valley Community Research Initiative
Palm Springs
California
Desert AIDS Project
Palm Springs
California
Disabled In Action of Metropolitan NY
New York
New York
Equitas Health
Columbus
Ohio
H.O.P.E. Alliance
Albuquerque
New Mexico
Health GAP
Washington
District of Columbia
House of Blahnik, Inc.
Philadelphia
Pennsylvania
Housing Works
Brooklyn
New York
Housing Works, Inc.
New York
New York
Howard Brown Health
Chicago
Illinois
International Foundation for Alternative Research in AIDS
Portland
Oregon
Iris House
New York
New York
Latino Commission on AIDS
New York
New York
Los Angeles LGBT Center
Los Angeles
California
Louisiana AIDS Advocacy Network, Inc.
Lafayette
Louisiana
Migrant Clinicians Network
Austin
Texas
National Coalition for LGBT Health
Washington
District of Columbia
National Coalition of STD Directors
Washington
District of Columbia
National Health Coalition
Vancouver
Washington
National Network of STD Clinical Training Centers
Winston-Salem
North Carolina
National Network of STD Prevention Training Centers
New York
New York
Needle Exchange Emergency Distribution
Berkeley
California
New Jersey Association on Correction
Trenton
New Jersey
NMAC
Washington
District of Columbia
NNPTC
Denver
Colorado
Okaloosa AIDS Support & Informational Services, Inc.(OASIS)
Ft. Walton Beach
Florida
PeterCares House
Greenbelt
Maryland
POZabilities
San Diego
California
Prevention Access Campaign
Brooklyn
New York
Pride for Youth/Long Island Crisis Center
Bellmore
New York
Professionals For Humanity (PROFOH)
Houston
Texas
Project Inform
San Francisco
California
Red Gym Men’s Club
Syracuse
New York
Silver Creek Strategies
Novelty
Ohio
Siouxland Community Health Center
Sioux CIty
Iowa
Siouxland Pride Alliance
Sioux City
Iowa
Span, Inc.
Boston
Massachusetts
The Center For Black Equity Baltimore
Baltimore
Maryland
The CHANGE Coalition
New Orleans
Louisiana
The Hepatitis C Mentor and Support Group-HCMSG
New York City
New York
Trillium Health
Rochester
New York
Unity Fellowship Church
Brooklyn
New York
Women With A Vision, Inc
New Orleans
Louisiana
The following individuals:
Ace Robinson
Long Beach
California
Adam Bowen
San Jose
California
Adam Martin
New York
New York
Alice Gandelman
Oakland
California
Amita Gupta
Baltimore
Maryland
Andrea Cipriani
Oakland
California
Andy Humm
New York
New York
Anna Forbes, MSS
Kensington
Maryland
Anthony Gonzalez
San Francisco
California
Arthur Moswin MD
Chicago
Illinois
Audrey Sokoloff
New York
New York
Bella TSANG
Long Island City
New York
Bishop Pat Bumgardner
New York
New York
Bobby J. Long
San Diego
California
Bonnie Richardson
Chicago
Illinois
Brad Dalton
Houston
Texas
Brandon Kennedy
Chicago
Illinois
Brenda Wolfe
Chicago
Illinois
Bruce Richman
Brooklyn
New York
Bryan Jones
Cleveland
Ohio
Cameron R.Wolfe
Durham
North Carolina
Candace Kugel, FNP, CNM
Clinton
New York
Carl Stein, MHS, PAC
San Francisco
California
Caroline Teschke MD
Portland
Maine
Christine Snyder
Buffalo
New York
Christopher Destache
Omaha
Nebraska
Christopher Taylor Edwards
New York
New York
Clyde Johnson
Philadelphia
Pennsylvania
Clyde Johnson
Philadelphia
Pennsylvania
Courtney Voss
Sioux City
Iowa
Darlene Robertson
Port Barre
Louisiana
David Hubbell
Oak Park
Illinois
Debra East
Lander
Wyoming
Deliana Garcia
Austin
Texas
Derrick Mapp
San Francisco
California
Diana Nilsen
New York City
New York
Dominic Orlando
Lisle
Illinois
Dominique Cooper
Bethesda
American Samoa
Dr. Paul Bellman
New York City
New York
Dr.Rev.Abraham Calleros,PA,DD,HWHP
Yucca Valley
California
Drew Gibson
Washington
District of Columbia
Eamonn Vitt MD
New York
New York
Eduardo Culbeaux
Chicago
Illinois
Edward C Fagan
Kansas City
Missouri
Edward Kantor, MD
Charleston
South Carolina
Elizabeth Capone-Newton, MPH
Portland
Maine
Elizabeth Crutsinger-Perry
Olympia
Washington
Elizabeth Hagan
Philadelphia
Pennsylvania
Emily Sanderson
Brooklyn
New York
Eric Jannke
Palm Springs
California
Forrest Williams
New York
New York
Fred Schaich
Portland
Oregon
Garvin Scott McCurdy
San Francisco
California
Howard A. Grossman, MD
West Palm Beach
Florida
Ingrid N. Floyd
Plainfield
New Jersey
Irvin Parker IV`
New York
New York
Jacob Levi
London
New York
James Gilday
New York
New York
James Krellenstein
New York
New York
Jason Stout
Durham
North Carolina
Jeanmarie Zippo RN
Philadelphiia
Pennsylvania
Jeffrey Tornheim
Baltimore
Maryland
Jim Pickett
Chicago
Illinois
Joanne Alonso Byars
Fort Pierce
Florida
Joanne L. Delaney
Boston
Massachusetts
John Hamlin
Stamford
Connecticut
John McNevin
Seattle
Washington
John Nelson
Belleville
New Jersey
John Schuster
Washington
District of Columbia
John Stryker
Chicago
Illinois
Johnny Guaylupo
New York
New York
Joseph K Tate
Berkeley
California
Joseph Robert Winn
Arlington
Massachusetts
Joseph William Dluzak
New York City
New York
Joshua Thaden
Durham
North Carolina
Julie Fitch
New Orleans
Louisiana
Kathi Roussel
Buffalo
New York
Keith R. Green
Chicago
Illinois
Kelly Dooley
Baltimore
Maryland
Kenneth Hecht
Berkeley
California
Kenneth Wilson
Durham
North Carolina
Kevin Goetz
Los Angeles
California
Kurt Kemmerer
Portland
Oregon
Larry Kramer
New York
New York
Laura Morrison
New York
New York
Lauren Gauthier
New Orleans
Louisiana
Leiba Frans
Brooklyn
New York
Leslie Hughes
Buffalo
New York
Linda Infelise
Phoenix
Oregon
Logan McMaster
Islin
New Jersey
Luis Lira
Chicago
Illinois
Marco Castro-Bojorquez
Los Angeles
California
Margaret McCarthy
New Haven
Connecticut
Mark Brennan-Ing, PhD
New York
New York
Mark Leno
San Francisco
California
Mark Wyn
Saint Louis
Missouri
Marty S. Player MD, MS
Charleston
South Carolina
Maryblaise Larson
Madison
Connecticut
Matthew Franck
Highland Park
New Jersey
Maureen Murphy
Vallejo California
Maxwell Ciardullo
New Orleans
Louisiana
Melanie Thompson, MD
Atlanta
Georgia
Meredith Clement
Durham
North Carolina
Meredith Short
Bloomington
Indiana
Michael A Toth
Arlington
Virginia
Michael C Shapiro
Laguna Niguel
California
Michael Longacre
Sagaponack
New York
Michael Luciano
Charleston
South Carolina
MJ Schuman
New York
New York
Nelly Hugh-Jones
Baton Rouge
Louisiana
Nicholas Bennett
Lee’s Summit
Missouri
Nicholas Rice
New York
New York
Nicholas Turner MD
Durham
North Carolina
Nick Debs
Eastham
Massachusetts
Paul Chambliss, MD MPH
New York
New York
Paul VanSteenwyk
Tucson
Arizona
Penny DeNoble
New Orleans
Louisiana
Pete Carney
Middle Village
New York
Peter M Caesar, LICSW
Newburyport
Massachusetts
Professor Rebecca Jordan-Young
New York
New York
Rae Leiner
Newburgh
New York
Randal Lucero
Albuquerque
New Mexico
Raymond Egolf
Palm Harbor
Florida
Reginlad Brown
Brooklyn
New York
Richard Cardillo
New York
New York
Richard Kelso
New York
New York
Richard Pucciarelli
Matawan
New Jersey
Richard Uniszkiewicz
Murfreesboro
Tennessee
Rick Runabear
Vancouver
Washington
Robert Benjamin, MD, MPH
Orindal
California
Robert Levaro
Tucson
Arizona
Robert Marshall
New York
New York
Ronald Carthen
Rochester
New York
Ronald E. Macon
Worcester
Massachusetts
Roy Wadia
Decatur
Georgia
Sandra M. Palleja, MD
Bridgewater
New Jersey
Sandra Montgomery
Amherst
New York
Sara Onesi
Pittsburgh
Pennsylvania
Scott Oakley
Los Angeles
California
Sean McShee
Fort Lauderdale
Florida
Seth M. Bloom, MD, PhD
Boston
Massachusetts
Shawn Peterson
Portland
Maine
Sheila Reeves
Portland
Oregon
Stacey Ravanesi
Forest Park
Illinois
Stephen Corbett
Boston
Massachusetts
Suzy Subways
Philadelphia
Pennsylvania
Syria Jackson
New Orleans
Louisiana
T. Bailey
Kansas City
Missouri
Ted Hoyle
Southold
New York
Thomas Earl Lewis
Fraser
Michigan
Timothy Frasca
New York
New York
Tom Grogan
Cincinnati
Ohio
Vanessa Haney
New York
New York
Victoria A. Cargill, M.D., M.S.C.E.
Newark
Delaware
Victoria Hoverman
Gaithersburg
Maryland
Wade Louis Rosenthal
Brooklyn
New York
William Boemer
San Rafael
California
Willy Quesada
Bridgeport
Connecticut
Witti Repartee
New York
New York
Xavier Erguera
San Francisco
California
[i] Wyber R, et al. Benzathine Penicillin G for the Management of RHD: Concerns About Quality and Access, and Opportunities for Intervention and Improvement. Glob Heart. 2013 Sep;8(3):227-34. doi: 10.1016/j.gheart.2013.08.011.
[ii] Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance 2015. Atlanta: U.S. Department of Health and Human Services; 2016. https://www.cdc.gov/std/stats15/syphilis.htm
[iii] “Fortune 500.” Forbes. [Internet]. http://fortune.com/fortune500/list/